G2GBIO Inc.

₩35,100As of Sun 8 Nov 2026, 12:00 UTC

KOSDAQ:456160Healthcare

Country South Korea

PE (Fwd) 347.8

TSR 10Y CAGR —

Div yield —

ROE (12.69%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (36.95%)

Mkt cap ₩583.7B

ROIC (7.46%)

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

₩37,901

—

7.98%

—

—

TTM

FYE 31 Dec KRW

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

2.215

Revenue₩B

—

—

—

—

—

—

—

—

0.769

0.423

1.643

(44.98%)

—

—

—

Revenue growth%

—

—

—

—

—

—

—

—

—

(44.98)

288.43

(44.98)

—

—

36.20

Gross margin%

—

—

—

—

—

—

—

—

24.75

(7.91)

19.87

8.42

—

—

(568.74)

Operating margin%

—

—

—

—

—

—

—

—

(1399.80)

(2884.22)

(100.00)

(2142.01)

—

—

(793.67)

Net margin%

—

—

—

—

—

—

—

—

(10827.32)

(2857.07)

100.00

(6842.19)

—

—

—

P/E ratio (avg)x

—

—

—

—

—

—

—

—

—

—

299.5

—

—

—

—

EV/EBITx

—

—

—

—

—

—

—

—

—

—

—

—

—

—

(2.70)

FCF yield (avg)%

—

—

—

—

—

—

—

—

—

(1.42)

(0.33)

(1.42)

—

—

(711.00)

FCF margin%

—

—

—

—

—

—

—

—

(1112.18)

(3367.09)

(100.00)

(2239.64)

—

—

0.896

FCF / Net incomex

—

—

—

—

—

—

—

—

0.103

1.179

(1.000)

0.641

—

—

(7.46)

ROIC%

—

—

—

—

—

—

—

—

—

—

(0.97)

—

—

—

(12.69)

Return on equity%

—

—

—

—

—

—

—

—

—

—

1.18

—

—

—

(7.48)

Return on assets%

—

—

—

—

—

—

—

—

(328.48)

(17.84)

0.70

(173.16)

—

—

(1,059)

EPS₩

—

—

—

—

—

—

—

—

—

(862.00)

117.19

—

—

—

—

EPS growth%

—

—

—

—

—

—

—

—

—

—

113.60

—

—

—

8,351

Bookvalue per sh₩

—

—

—

—

—

—

—

—

—

4,160

9,944

—

—

—

(949.00)

FCF per share₩

—

—

—

—

—

—

—

—

—

(1,016)

(117.19)

—

—

—

—

Dividend per sh₩

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Div yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Payout ratio%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

16.63

Shares (diluted)M

—

—

—

—

—

—

—

—

—

14.02

◌14.02

—

—

—

—

Buyback yield%

—

—

—

—

—

—

—

—

—

—

◌—

—

—

—

0.301

D/E ratiox

—

—

—

—

—

—

—

—

(0.132)

0.122

0.300

—

—

—

618.0

Enterprise value₩B

—

—

—

—

—

—

—

—

—

999.9

523.3

—

—

—

0.733

LT debt₩B

—

—

—

—

—

—

—

—

1.424

0.917

0.733

(35.65%)

—

—

Peers (US$370.3M)

Cap (US$)

PE

ImmuneOncia Therapeuti…

160.4M

—

Vivozon Pharmaceutical…

131.5M

—

GC WellBeing Corporati…

121.3M

34.05x

Taho Pharmaceuticals…

372.8M

—

Capital

TTM

5Y

10Y

Leveragex

—

—

—

EBIT/Intx

(4.491)

(10.83)

(10.83)

Own earn%

—

—

—

Sh yield%

—

—

—

Owners

Insiders/Inst%

18.41

4.51

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

—

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

—

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products.

Growth vs revenue

Latest

Trend

1Y CAGR

Rel growth

Revenue

₩423.1M

(44.98%)

1.00×

Cost of revenue

₩456.6M

(21.09%)

1.43×

Operating expenses

₩12.17B

11.09%

2.02×

Asset mix

Share

Trend

Other

87.67%

Cash and investments

11.77%

Goodwill & intangibles

0.56%

Reinvestment returns

No breakdown available